（来源：名城苏州网） 鲲石生物凭借其独创的四大技术平台，从根源上解决了自体CAR-M疗法"难转导、成本高、周期长、抗 肿瘤能力弱"的核心难题。 病毒改造技术突破 转自：名城苏州网 鲲石自主研发的巨噬细胞特异性病毒改造技术，将腺病毒与慢病毒对巨噬细胞的转导效率提升至90%以 上，解决CAR-M基因递送效率低下的行业难题。 BioBAY园内企业鲲石生物近日完成 5000 万元人民币 A 轮融资，用于深入推进其全球领先的巨噬细胞 药物研发及临床转化。 第三代CAR-M 本轮融资将重点用于公司全球领先的巨噬细胞药物平台建设，加速推进自主研发的第三代 CAR-M 靶向 HER2 管线的 IND 申报、一期临床进程以及胰腺癌，肺癌等管线临床前研究和 IIT 探索。此次融资的顺 利完成，不仅体现了资本市场对公司在巨噬细胞药物领域创新能力和研发进展的高度认可，也为后续临 床转化奠定了坚实基础。 鲲石全球首创第三代CAR-M串联了巨噬细胞自体增殖活化所必需的细胞因子，促进CAR-M长期存活， 改变肿瘤微环境，已经完成10例患者的IIT临床试验。 体内CAR-M技术 技术平台驱动，破解 CAR-M 成药难题 临床数据亮眼，验证" ...

Group 1 - The company forecasts a net profit attributable to shareholders of the parent company for 2025 to be between -85 million yuan and -66 million yuan [2] - The forecasted net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between -84 million yuan and -65 million yuan [3] - The financial data in this performance forecast has not been audited by a registered accountant [4] Group 2 - In the same period last year, the total profit was -54.2183 million yuan, with a net profit attributable to shareholders of the parent company at -54.4163 million yuan, and a net profit after deducting non-recurring gains and losses at -71.7486 million yuan [5] - The earnings per share for the previous year was -0.78 yuan per share [6] Group 3 - The main reasons for the performance changes include an increase in revenue from the main business due to the continuous enrichment of the product line and the development of new business [6] - The company has increased its R&D investment in areas such as RNA drugs, antibody drugs, gene and cell therapy, organoids, and synthetic biology to strengthen its technological advantages [6] - The company has expanded its marketing team and enhanced brand marketing efforts, leading to an increase in sales expenses [6] - A reduction in government subsidies compared to the previous year has been noted, impacting other income [7]

Group 1: Market Performance - Hong Kong's innovative drug ETF (159570) surged by 3%, with a trading volume exceeding 1.5 billion yuan, following a net inflow of over 62 million yuan today after a previous inflow of 430 million yuan [1][3] - As of January 6, the latest scale of the Hong Kong innovative drug ETF reached over 23.3 billion yuan, leading its peers in the same category [1] Group 2: Economic Signals - Federal Reserve Governor Milan indicated that upcoming economic data may support further interest rate cuts, with expectations of a reduction exceeding 100 basis points this year [3] - Wall Street analysts suggest that if the U.S. unemployment rate rises to 4.7% by December 2025, the Fed may cut rates by 25 basis points this month [3] Group 3: Company Developments - Brain-computer interface "unicorn" Strong Brain Technology completed a financing round of 2 billion yuan, second only to Musk's Neuralink [3] - AI pharmaceutical company Insilico Medicine announced a long-term collaboration with Siveya for anti-tumor drug development, with a total deal value of 888 million USD [3] Group 4: New Drug Approvals - On January 6, BeiGene announced that its self-developed BCL2 inhibitor, Baiyueda® (sotucumab), received conditional approval from the National Medical Products Administration [3] - Shiyao's SYS6017 has initiated Phase II clinical trials for the prevention of shingles [3] Group 5: Investment Insights - Zhongtai Securities predicts that the pharmaceutical sector's opportunities in 2025 will focus on innovation and industry upgrades, with investment strategies continuing into 2026 [5] - The report emphasizes the importance of "innovative drugs and industry chains, demand recovery, and AI" as key investment dimensions [5] Group 6: J.P. Morgan Healthcare Conference - The 44th J.P. Morgan Healthcare Conference is set to take place from January 12 to 15, 2026, in San Francisco, attracting over 8,000 global participants [6] - The conference will feature over 500 listed companies and thousands of startups, focusing on "capital + strategy" discussions [6] Group 7: Industry Trends - Three major trends are highlighted for 2026: the continued rise of gene and cell therapies, deep integration of AI in pharmaceuticals, and the emergence of new market forces [7] - The report notes that over 20 gene editing companies will showcase breakthroughs in CAR-T and base editing at the conference [7] Group 8: MNC Engagement - Multinational corporations (MNCs) are willing to pay higher prices for innovative drugs from China, with the average total package for drugs purchased from China being 2.76 billion USD, compared to 1.29 billion USD for those from overseas [8] - The willingness of MNCs to pay a premium for Chinese innovations is driven by the need to fill significant pipeline gaps due to impending patent expirations [8] Group 9: Investment Focus - Investment strategies should focus on companies with strong clinical development capabilities and those in popular therapeutic areas such as ADCs, GLP-1, and dual antibodies [11] - Companies that can produce high-quality late-stage clinical assets are likely to attract MNC interest [11] Group 10: Key Therapeutic Areas - The report identifies key therapeutic areas for investment, including ADCs, GLP-1, dual antibodies, and neuroscience, emphasizing the need for innovative platforms and clinical data superiority [12]

编辑丨王多鱼 排版丨水成文 基因与细胞治疗正处于疾病创新性治疗手段的最前沿，已成为肿瘤、代谢性疾病、遗传病等多类重大疾病 的重要突破口，有望显著提升临床疗效并改善患者生活质量。然而，传统细胞与基因治疗在实际临床应用 中仍面临诸多挑战，例如给药方式复杂、体内调控精度不足以及患者长期治疗依从性较低等问题。 这些瓶 颈在一定程度上制约了相关技术从实验室走向临床转化。 在此背景下， 如何实现对 " 活体药物 " 的个性化、精准化和可控化调节 ，成为医学界、产业界和学术界 共同关注的前沿难题 。 阿洛酮糖 是一种天然存在的稀有单糖，已被美国食品药品监督管理局 （ FDA ） 认定为"普遍认为安全 （ GRAS ） "的食品成分。其甜度约为蔗糖的 70% ，热量极低，血糖生成指数接近于零，并被认为具有辅助 调节血糖和脂质代谢的潜在益处，因此广泛应用于无糖食品和饮料中。 2025 年，我国国家卫生健康委员 会亦正式批准阿洛酮糖作为新食品原料，为其在健康与生物医学领域的应用奠定了政策基础。 PURE 系统 以来源于土壤农杆菌 （ Agrobacterium tumefaciens ） 的转录因子 PsiR 为核心调控元件。 ...

Group 1: Market Performance - The Hong Kong stock market experienced a strong start in 2026, with the Hang Seng Index rising by 2.76% to 26,338.47 points, and the Hang Seng Technology Index increasing by 4% to 5,736.44 points [3] - The Hong Kong Innovation Drug ETF (159570) surged over 5.5%, with a trading volume exceeding 1.6 billion yuan, marking a significant increase compared to the previous trading day [1][3] - As of December 29, 2025, the latest scale of the Hong Kong Innovation Drug ETF reached over 21.4 billion yuan, leading its peers in the same category [1] Group 2: Company News - In a significant development, Insilico Medicine announced a multi-year research collaboration with Servier worth up to $888 million, focusing on oncology drug development [3] - The collaboration will leverage Insilico's AI-driven drug discovery platform, Pharma.AI, in conjunction with Servier's global expertise in oncology [3] - Insilico is eligible for an upfront payment of up to $32 million and milestone payments related to research achievements [3] Group 3: Industry Trends - In 2025, the Chinese innovative drug industry set a record for outbound licensing transactions, with a total transaction value of $135.655 billion and 157 deals, marking a historical high [5] - The industry is witnessing a diversification in business development (BD) models, with an increasing number of innovative drug companies opting for co-development partnerships with multinational pharmaceutical firms [7][10] - The "Co-Co" (Co-development & Co-commercialization) model is emerging as a significant trend in 2025, exemplified by the $11.4 billion deal between Innovent Biologics and Takeda [11]

Core Viewpoint - The Hong Kong pharmaceutical market is experiencing a downturn, with the Hong Kong Stock Connect Innovation Drug ETF (159570) declining by 1.14% and over 25% from its previous high, despite a significant trading volume of over 1.44 billion yuan [1][4]. Group 1: Market Performance - The Hong Kong Stock Connect Innovation Drug ETF (159570) has seen a three-day decline, reaching a new low, with a total trading volume exceeding 14.4 billion yuan [1]. - As of December 29, the latest scale of the Hong Kong Stock Connect Innovation Drug ETF (159570) is over 21.9 billion yuan, leading among its peers [1]. - Major stocks within the ETF, such as King’s Bio and Kelun-Bio, have experienced declines, with King’s Bio dropping over 3% [4][5]. Group 2: IPO Activity - On December 30, Insilico Medicine, a generative AI-driven biopharmaceutical company, successfully listed on the Hong Kong Stock Exchange, marking it as the first AI biopharmaceutical company to do so under the main board listing rules [3]. - The IPO raised a total of 2.277 billion Hong Kong dollars, making it the highest fundraising biopharmaceutical IPO in Hong Kong for the year [3]. Group 3: Industry Trends - The upcoming J.P. Morgan Healthcare Conference in January 2026 is expected to attract over 8,000 global participants, featuring more than 500 listed companies and thousands of startups, focusing on "capital + strategy" discussions [6]. - Key trends highlighted for the industry include the continued rise of gene and cell therapies, deep integration of AI in pharmaceuticals, and the emergence of new market forces from China [7]. Group 4: Investment Insights - Multinational corporations (MNCs) are willing to pay higher prices for innovative drugs and technology platforms from China, with average total deals from China reaching 2.756 billion USD compared to 1.289 billion USD from overseas [8]. - The pressure from patent expirations, estimated at around 300 billion USD in sales, is driving MNCs to seek high-potential assets in China, particularly in advanced fields like ADCs and cell therapies [9]. - MNCs are shifting their focus from merely acquiring products to obtaining platforms and technologies that can yield new molecules, indicating a strategic evolution in their investment approach [10]. Group 5: Key Investment Areas - Key investment areas include ADCs, GLP-1 for metabolic diseases, bispecific antibodies, and neuroscience, with a focus on companies that can deliver competitive clinical data and innovative platforms [12][13].

Core Insights - The 2025 China Biotechnology Innovation Conference opened in Chengdu High-tech Zone, gathering over 1,000 experts and representatives from more than 50 well-known pharmaceutical companies to discuss the future of the global health industry [1][3] Event Overview - The conference, hosted by the China Biotechnology Development Center and organized by the Chengdu High-tech Zone Management Committee, spans three days and includes an opening ceremony, 14 sessions of sub-forums, technology achievement roadshows, and closed-door meetings [3] - The event features a comprehensive presentation of the latest dynamics, core challenges, and development opportunities in global biotechnology innovation through various formats [3] Key Reports and Presentations - The "2024 China Biopharmaceutical Park Competitiveness Ranking" was unveiled during the opening ceremony, with Chengdu High-tech Zone maintaining a leading position [3][5] - Notable presentations included: - A report by Academician Cao Xuetao on the strategic planning for innovative drug development over the next decade and the new era of biopharmaceuticals [3] - A report by Academician Chen Kaixian analyzing the development trends and innovation strategies in the chemical drug sector [4] - A report by Academician Chen Shilin discussing technological breakthroughs in the full industry chain development of traditional Chinese medicine [4] Specialized Sessions - The conference includes 14 specialized sessions covering topics such as AI-enabled innovative drug development, gene and cell therapy, modernization of traditional Chinese medicine, advanced industrial biotechnology, and disruptive technologies [4] Industry Reports - Four authoritative reports were released, including the "2025 China Life Sciences and Biotechnology Development Report" and the "2025 China Clinical Research Development Report," providing critical insights for industry development [5] - The "2025 China Biopharmaceutical Park Development Status Analysis Report" highlighted the competitive advantages of cities in biotechnology, with Chengdu High-tech Zone ranking alongside other leading innovation districts [5] New Initiatives - The "Global New Drug Discovery Center" was officially launched, aiming to integrate resources from over 3,000 biopharmaceutical companies in the region to create a comprehensive service system for drug discovery [6] - Chengdu High-tech Zone is focused on building a robust biopharmaceutical innovation ecosystem, enhancing collaboration between government, industry, academia, and research institutions to drive technological breakthroughs [6]

Core Insights - The 10th Pharmaceutical Innovation and Investment Conference will be held on October 26-27 in Nanjing, focusing on global pharmaceutical R&D dynamics and fostering collaboration in the industry [1][8] - The conference will feature a diverse range of discussions, including AI in drug development, gene and cell therapy, and innovations in rare diseases and pediatric medicine [7][8] Event Structure - The opening ceremony will include speeches from key figures such as the Vice President of the China Pharmaceutical Innovation Promotion Association and leaders from the pharmaceutical industry [4][5] - The conference will consist of multiple phases, including keynote speeches and panel discussions on topics like technological innovation and investment trends [5][6] Networking and Collaboration - The conference aims to facilitate deep collaboration through a one-on-one business negotiation system, enhancing communication and partnership opportunities among participants [9] - A special on-site experience will allow attendees to engage with the core resources of the biopharmaceutical industry in the Yangtze River Delta, showcasing the entire innovation ecosystem from R&D to commercialization [10] Industry Impact - The conference has historically attracted leaders from government, academia, and investment sectors, providing insights and practical experiences that shape industry trends [8] - Over 60 participating companies have successfully gone public, highlighting the conference's role in driving investment and innovation in the pharmaceutical sector [10]

Core Insights - Nanjing Biomedicine Valley has introduced over 50 innovative products and technologies that are first in the world or country, highlighting its role as a key player in the biomedicine industry [1] - The region is focusing on precision medicine and niche areas such as brain science and gene therapy, aiming to establish a comprehensive innovation ecosystem [2][3] - Two new class 1 drugs have been approved this year, marking a significant achievement for the Nanjing Biomedicine Valley [3][4] Industry Overview - The global biomedicine industry is accelerating towards precision diagnosis and treatment, with Nanjing Biomedicine Valley positioning itself in niche markets [2] - The region has established a full industrial chain in gene and cell therapy, including gene testing, diagnostics, and CAR-T cell therapy [3] - The Nanjing Biomedicine Valley has attracted over 1,300 companies, with 7 companies successfully listed and 6 class 1 drugs approved [5] Innovation and Development - The Nanjing Biomedicine Valley is enhancing its innovation capabilities by collaborating with universities and establishing technology transfer centers [6] - A total of 84 billion yuan fund support plan has been launched to facilitate the transformation of scientific achievements from universities [6] - The region is focusing on building a robust innovation ecosystem that integrates innovation chains, industry chains, capital chains, and talent chains [7] Recent Achievements - The approval of two class 1 drugs, Enze Shou and Ji Ke Shu, represents a milestone for the biomedicine valley, with the former being the first targeted drug for platinum-resistant ovarian cancer in China [3][4] - The establishment of the Jiangsu Brain Intelligence Technology Innovation Center aims to make breakthroughs in brain science over the next five years [2] - The Nanjing Biomedicine Valley has successfully facilitated the listing of companies and the approval of innovative drugs, showcasing its supportive environment for biomedicine enterprises [5][6]

Core Viewpoint - The seventh Pharmaceutical Frontier Academic Forum emphasizes the importance of original drug development and the role of artificial intelligence in accelerating the drug research and development process [1] Group 1: Forum Highlights - The forum, held in Nanjing, focuses on cutting-edge areas such as gene and cell therapy, advanced formulations and delivery technologies, and AI in new drug development [1] - Experts discuss the collaborative development path from source innovation to clinical transformation [1] Group 2: Key Statements - Chen Kaixian, the forum chairman and an academician of the Chinese Academy of Sciences, highlights that developing original new drugs is crucial for building new productive forces in biomedicine and achieving a strong technological nation in this field [1] - The use of artificial intelligence is noted as a key technology in drug research, with an example of an AI chemist at the University of Liverpool working 21.5 hours a day [1] - Future advancements are expected in automated molecular manufacturing, automated biological laboratories, and virtual clinical laboratories, leading to efficient and precise synthesis and continuous manufacturing of drug molecules [1]